// App-Quantinova.ai

e17013 : Phase 2 analysis on Covid-19-adopted etoposide (E) and cisplatin (P) regimens for patients (pts) with an advanced germ cell tumor (GCT): The CovGCT study.

Researchers

Presenter

  • Nabeel Naban

Principal Investigators

  • Gesa Tiemeier

  • Arwa Kocache

  • Rory Taylor

  • Georgina Keogh

  • Lindsay Hennah

  • Naveed Sarwar

  • Michael Seckl

  • Michael Gonzalez

Medical Centers

  • Imperial College, London, United Kingdom

  • Charing Cross Hospital, Imperial College Healthcare National Health Service (NHS) Trust, London, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

  • Oncology (ONC)

Disease

  • Germ cell tumor

  • Coronavirus disease

Biomarkers

  • N/A

Drug/Treatment

  • Etoposide

  • Etoposide phosphate

  • Cisplatin

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved